Added to YB: 2026-06-08
Pitch date: 2026-06-04
NAUT [neutral]
Nautilus Biotechnology, Inc.
-9.81%
current return
Author Info
The Micro-Capo is a blog where I share news and articles on companies I like or own. Sign up for the newsletter.
Company Info
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Market Cap
$303.7M
Pitch Price
$2.65
Price Target
8.00 (+235%)
Dividend
N/A
EV/EBITDA
-4.58
P/E
-5.29
EV/Sales
N/A
Sector
Life Sciences Tools and Services
Category
growth
Monthly Report - Nautilus Biotechnology, Inc.
NAUT (earnings): Q1 2026 EPS -$0.12 beat -$0.17 est (+29.4%), stock +11.6% pre-mkt. Opex -14% YoY to $16.1M; $143.4M cash, runway thru 2027. Oncology proteoform assay enters Early Access H2 2026 (2nd after tau); sales team onboarded. Commercial launch late 2026. PT $8 (+188%). On track.
Read full article (1 min)